📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Gujarat Themis Biosyn Q3 Net Profit Dips 4% to ₹12.46 Cr; Appoints New CFO
Gujarat Themis Biosyn reported a 10.1% year-on-year increase in total income to ₹43.78 crore for Q3 FY26. However, net profit for the quarter declined by 3.9% to ₹12.46 crore, primarily due to a significant rise in depreciation and employee benefit expenses. The company also announced a management transition, with Krupesh Patel appointed as the new CFO effective April 1, 2026, as the current CFO moves to a plant-level accounting role. The 9-month net profit stands at ₹35.79 crore, slightly lower than the ₹36.77 crore recorded in the previous year.
Key Highlights
Total Income for Q3 FY26 rose to ₹4,378.45 Lakhs from ₹3,976.15 Lakhs in Q3 FY25.
Net Profit after tax decreased to ₹1,246.46 Lakhs compared to ₹1,297.23 Lakhs in the same quarter last year.
Depreciation and Amortization expenses more than doubled to ₹388.81 Lakhs from ₹156.33 Lakhs YoY.
Mr. Krupesh Patel, an MBA/CS/ICWA professional, is appointed as CFO effective April 1, 2026.
A one-time financial impact of ₹13.36 lakhs was recognized following the notification of new Labour Codes.
💼 Action for Investors
Investors should monitor the company's ability to scale revenue to offset the rising depreciation costs associated with recent capital expenditures. The stock remains a hold as core operations show steady revenue growth despite temporary margin pressure.
GUJTHEM Q3 Revenue Up 10%, EBITDA Up 13%; New API Unit and 18.5 MW Power Plant Progressing
Gujarat Themis Biosyn reported a 9.74% YoY increase in Q3 FY26 revenue to ₹43.37 crore, supported by healthy demand and volume growth. EBITDA grew 12.93% to ₹22.06 crore with strong margins of 49.13%, although PAT declined slightly by 3.92% to ₹12.46 crore due to higher depreciation and interest from recent capex. The company is successfully transitioning toward forward integration, having completed validation batches in its new API block. Furthermore, a new 18.5 MW hybrid renewable power plant is being established to optimize long-term power costs and enhance sustainability.
Key Highlights
Q3 FY26 Revenue increased 9.74% YoY to ₹43.37 crore with EBITDA margins improving 139 bps to 49.13%.
Completed new fermentation facility and finished validation batches for the forward-integrated API production block.
Setting up a 18.5 MW Wind-Solar hybrid power plant for captive consumption to reduce grid dependence and costs.
R&D expenditure maintained at 3% of revenue for the 9-month period to drive new product development.
Net Block (Property, Plant & Equipment) increased significantly to ₹159.36 crore as major capex projects are capitalized.
💼 Action for Investors
Investors should focus on the successful commercialization and ramp-up of the new API facility which marks a shift in the business model. While depreciation and interest costs may weigh on PAT in the short term, the forward integration and captive power project are strong long-term margin drivers.
Gujarat Themis Biosyn Q3 Profit at ₹12.46 Cr; Appoints Krupesh Patel as New CFO
Gujarat Themis Biosyn Limited reported a 10.1% YoY increase in total income to ₹43.78 crore for Q3 FY26. However, net profit saw a slight decline to ₹12.46 crore from ₹12.97 crore in the previous year's corresponding quarter, largely due to a significant rise in depreciation and employee expenses. The company also announced a strategic management transition, appointing Mr. Krupesh Patel as the new CFO effective April 1, 2026, as the current CFO moves to a plant-focused accounting role. Additionally, the board approved the re-appointment of Ms. Kirandeep Madan as an Independent Director for a second five-year term.
Key Highlights
Total Income for Q3 FY26 rose to ₹4,378.45 Lakhs compared to ₹3,976.15 Lakhs in Q3 FY25.
Net Profit after tax decreased by 3.9% YoY to ₹1,246.46 Lakhs due to higher operational costs.
Depreciation and Amortisation expenses more than doubled to ₹388.81 Lakhs from ₹156.33 Lakhs YoY.
Mr. Krupesh Patel appointed as CFO starting April 2026, bringing 15 years of experience from Tata Advanced Systems and Lupin.
Current CFO Mr. Bhavik Shah to transition to Senior Accounts Manager to focus on plant-related accounting and ongoing projects.
💼 Action for Investors
Investors should note the margin pressure caused by rising depreciation and employee costs despite steady revenue growth. The transition in the finance department appears to be a planned internal restructuring to strengthen plant-level operations and corporate finance separately.
Gujarat Themis Biosyn Q3 Revenue Up 10% YoY; Appoints Krupesh Patel as New CFO
Gujarat Themis Biosyn reported a 10.1% YoY increase in total income for Q3 FY26, reaching ₹4,378.45 lakhs. Despite the revenue growth, net profit slightly declined by 3.9% YoY to ₹1,246.46 lakhs, impacted by a significant rise in depreciation and employee costs. The company announced a management transition with Mr. Krupesh Patel taking over as CFO from April 1, 2026, as the incumbent moves to a plant-level role. Additionally, Ms. Kirandeep Madan was re-appointed as an Independent Director for a second five-year term.
Key Highlights
Total income for Q3 FY26 grew to ₹4,378.45 lakhs from ₹3,976.15 lakhs in Q3 FY25.
Net profit for the quarter stood at ₹1,246.46 lakhs, a marginal decrease from ₹1,297.23 lakhs YoY.
Depreciation and Amortization expenses more than doubled to ₹388.81 lakhs compared to ₹156.33 lakhs in the previous year.
Mr. Krupesh Patel appointed as CFO effective April 1, 2026, bringing 15 years of experience from firms like Tata Advanced Systems and Wockhardt.
Nine-month net profit for FY26 reached ₹3,579.03 lakhs compared to ₹3,677.35 lakhs in the corresponding period last year.
💼 Action for Investors
Investors should monitor if the increased depreciation, likely stemming from recent capital expenditure, leads to higher production capacity and revenue in coming quarters. The management transition appears orderly, but the slight dip in profitability despite revenue growth warrants a cautious watch on operating margins.
Gujarat Themis Biosyn Q3 FY26: Revenue Up 9.7% YoY to ₹43.37 Cr, Net Profit Dips to ₹12.46 Cr
Gujarat Themis Biosyn Limited reported a 9.7% YoY increase in revenue from operations, reaching ₹43.37 crore for the quarter ended December 31, 2025. Despite the revenue growth, net profit declined to ₹12.46 crore from ₹12.97 crore in the same period last year, primarily due to a sharp rise in depreciation and employee benefit expenses. The company also announced a leadership transition with Mr. Krupesh Patel appointed as the new CFO effective April 1, 2026. For the nine-month period, the company's net profit stands at ₹35.79 crore, slightly lower than the ₹36.77 crore recorded in the previous year.
Key Highlights
Revenue from operations grew 9.7% YoY to ₹43.37 crore compared to ₹39.52 crore in Q3 FY25.
Net profit after tax stood at ₹12.46 crore, down 3.9% YoY and 12.6% QoQ.
Depreciation and Amortization expenses surged to ₹3.89 crore from ₹1.56 crore in the year-ago quarter.
Employee benefit expenses increased significantly to ₹4.76 crore from ₹3.02 crore YoY.
Mr. Krupesh Patel appointed as CFO effective April 1, 2026, succeeding Mr. Bhavik Shah who is transitioning to a different role.
💼 Action for Investors
Investors should monitor the margin pressure resulting from increased depreciation and employee costs despite steady revenue growth. The transition in the CFO role and the impact of ongoing projects on future profitability remain key areas to watch.